Pars plana vitrectomy under melphalan irrigation for recurrent retinal detachment in eyes treated for retinoblastoma: a case report.
Child
Child, Preschool
Female
Humans
Male
Melphalan
/ administration & dosage
Myeloablative Agonists
/ administration & dosage
Retinal Detachment
/ diagnosis
Retinal Neoplasms
/ diagnosis
Retinoblastoma
/ diagnosis
Therapeutic Irrigation
/ adverse effects
Tomography, Optical Coherence
Vitrectomy
/ methods
Pars plana vitrectomy
Retinoblastoma
melphalan irrigation
tractional retinal detachment
Journal
BMC ophthalmology
ISSN: 1471-2415
Titre abrégé: BMC Ophthalmol
Pays: England
ID NLM: 100967802
Informations de publication
Date de publication:
28 Jan 2020
28 Jan 2020
Historique:
received:
27
06
2019
accepted:
13
01
2020
entrez:
30
1
2020
pubmed:
30
1
2020
medline:
15
12
2020
Statut:
epublish
Résumé
Tractional retinal detachment with or without secondary tear is a rare complication reported in less than 0.5% of in eyes treated for retinoblastoma. Pars plana vitrectomy (PPV) in eyes with history of retinoblastoma has been associated with a significant risk for recurrence, extraocular spread, and systemic metastases. We report here the successful management by PPV under melphalan irrigation of 2 children presenting with tractional retinal detachment after retinoblastoma therapy and scleral buckle surgery. A 7-year-old girl with a history of bilateral retinoblastoma (group D) presented with light perception best-corrected visual acuity (BCVA) and tractional retinal detachment (RD) in her left eye, 3 years after the last intra-arterial chemotherapy (IAC) injection. Moreover, she had history of left eye rhegmatogenous RD treated by scleral buckle 1 month after the last IAC and cataract surgery 12 months later. PPV associated with retinectomy, laser photocoagulation and silicone oil tamponade was performed. Silicone oil was removed 4 months later. Fifteen months after PPV, BCVA had increased to 20/32 without recurrence of RD and no evidence of tumor activity. A 7-year-old boy with a history of unilateral retinoblastoma (group D) in his left eye presented with rhegmatogenous RD 21 months after the last treatment for retinoblastoma. Scleral buckle surgery was performed, but 3 weeks later the patient presented with tractional RD associated with proliferative vitreo-retinopathy. BCVA was counting fingers. PPV associated with membrane peel, laser photocoagulation and silicone oil tamponade was performed. Silicone oil was removed after 5 months followed by cataract surgery 5 months later. Twenty months after PPV, BCVA was 20/20 and there was no sign of tumor recurrence. PPV under melphalan irrigation, with retinectomy, if necessary, and silicone oil tamponade, allows anatomical and functional improvement in eyes with history of retinoblastoma and scleral buckling developing tractional RD.
Sections du résumé
BACKGROUND
BACKGROUND
Tractional retinal detachment with or without secondary tear is a rare complication reported in less than 0.5% of in eyes treated for retinoblastoma. Pars plana vitrectomy (PPV) in eyes with history of retinoblastoma has been associated with a significant risk for recurrence, extraocular spread, and systemic metastases. We report here the successful management by PPV under melphalan irrigation of 2 children presenting with tractional retinal detachment after retinoblastoma therapy and scleral buckle surgery.
CASE PRESENTATION
METHODS
A 7-year-old girl with a history of bilateral retinoblastoma (group D) presented with light perception best-corrected visual acuity (BCVA) and tractional retinal detachment (RD) in her left eye, 3 years after the last intra-arterial chemotherapy (IAC) injection. Moreover, she had history of left eye rhegmatogenous RD treated by scleral buckle 1 month after the last IAC and cataract surgery 12 months later. PPV associated with retinectomy, laser photocoagulation and silicone oil tamponade was performed. Silicone oil was removed 4 months later. Fifteen months after PPV, BCVA had increased to 20/32 without recurrence of RD and no evidence of tumor activity. A 7-year-old boy with a history of unilateral retinoblastoma (group D) in his left eye presented with rhegmatogenous RD 21 months after the last treatment for retinoblastoma. Scleral buckle surgery was performed, but 3 weeks later the patient presented with tractional RD associated with proliferative vitreo-retinopathy. BCVA was counting fingers. PPV associated with membrane peel, laser photocoagulation and silicone oil tamponade was performed. Silicone oil was removed after 5 months followed by cataract surgery 5 months later. Twenty months after PPV, BCVA was 20/20 and there was no sign of tumor recurrence.
CONCLUSIONS
CONCLUSIONS
PPV under melphalan irrigation, with retinectomy, if necessary, and silicone oil tamponade, allows anatomical and functional improvement in eyes with history of retinoblastoma and scleral buckling developing tractional RD.
Identifiants
pubmed: 31992247
doi: 10.1186/s12886-020-1315-7
pii: 10.1186/s12886-020-1315-7
pmc: PMC6986012
doi:
Substances chimiques
Myeloablative Agonists
0
Melphalan
Q41OR9510P
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
34Références
Am J Ophthalmol. 1997 Jan;123(1):140-2
pubmed: 9186118
J Pediatr Ophthalmol Strabismus. 2010 Nov-Dec;47(6):349-55
pubmed: 20055334
Ophthalmol Clin North Am. 2005 Mar;18(1):41-53, viii
pubmed: 15763190
Ophthalmology. 1998 Nov;105(11):2134-9
pubmed: 9818618
Arch Ophthalmol. 2001 Nov;119(11):1613-21
pubmed: 11709011
Retina. 2006 Sep;26(7 Suppl):S53-6
pubmed: 16946680
Retin Cases Brief Rep. 2014 Summer;8(3):223-6
pubmed: 25372444
Retina. 2000;20(1):28-32
pubmed: 10696743
Ophthalmol Retina. 2017 Mar-Apr;1(2):165-172
pubmed: 28435935
Retina. 2006 Sep;26(7 Suppl):S47-52
pubmed: 16946679
Am J Ophthalmol. 2000 Jun;129(6):817-9
pubmed: 10927003
Ophthalmic Genet. 2016 Sep;37(3):314-7
pubmed: 26849063
Retina. 2017 Aug;37(8):1441-1450
pubmed: 27787452
Graefes Arch Clin Exp Ophthalmol. 2008 Apr;246(4):501-8
pubmed: 17934752
Ophthalmic Genet. 1999 Sep;20(3):141-51
pubmed: 10520235
Eur J Ophthalmol. 2015 Dec 01;26(1):e17-9
pubmed: 26428220
J Curr Ophthalmol. 2018 Sep 22;31(1):43-48
pubmed: 30899845